|
The principals of THE SAGE GROUP may own stock in the companies included in the research reports. At the end of the fourth quarter 2011 we owned the following securities: Aastrom Biosciences, Inc. Abbott Laboratories, Inc. Angiodynamics Inc. Vermillion Inc. |
According to PAD is not just a leg problem. PAD is a marker for severe systemic atherosclerosis as evidenced by the high morbidity and mortality. Research has shown that within 5 years approximately 50% will experience a cardiovascular event (defined as a heart attack or stroke) and 30% of these will be fatal. This 5-year mortality rate is higher than that of breast cancer, coronary artery disease and stroke. (Volume I and Volume II) |
